Drug intelligence / Profile preview

Inactivated H7N9 Influenza Vaccine

Development stage: Phase 2
Lead developer: Shanghai Institute of Biological Products
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous, Intranasal

Overview

The Inactivated H7N9 Influenza Vaccine is an inactivated, whole-virion preparation derived from the influenza A/Shanghai/2/2013(H7N9) virus. It is propagated in embryonated chicken eggs and formulated with aluminum hydroxide adjuvant. This vaccine is being developed to investigate its immunogenicity and safety in teenagers and adults, aiming to prevent H7N9 influenza infection.

Other names: H7N9 inactivated whole-virion vaccineH-7N9 inactivated whole-virion vaccineH 7N9 inactivated whole-virion vaccinealum-adjuvanted inactivated H7N9 influenza vaccineSIBP H7N9 vaccineinactivated whole-virion H7N9 vaccine

Targets

H7N9 antigen (Influenza A virus H7N9 antigen)

Beyond the preview

Go deeper on Inactivated H7N9 Influenza Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inactivated H7N9 Influenza Vaccine.

Explore the full profile